ADU S100

Drug Profile

ADU S100

Alternative Names: ADU-S100; MIW 815

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Novartis
  • Class Antineoplastics; Cyclic peptides; Nucleotides; Small molecules
  • Mechanism of Action Gene stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 08 Sep 2017 Phase-I clinical trials in Solid tumours and Lymphoma (Combination therapy, Late-stage disease, Metastatic disease) in USA (Intratumoural) (NCT03172936)
  • 09 Aug 2017 Aduro Bitoech and University of California at Berkeley collaborate for development of new immunotherapies before August 2017
  • 09 Aug 2017 Aduro Biotech and University of California receives patent allowance for ADU S100 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top